Paid Clinical Trials Yuma
Discover 22 paid clinical trials in Yuma, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
LasmiditanA 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT04396574
Conditions
Migraine
Eligibility Criteria
Sex: All
Age: 6 - 17
Healthy Volunteers: Not accepted
Interventions
Lasmiditan
V940 vs. PembrolizumabA Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06077760
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
V940
Pembrolizumab
Placebo
SP-624A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Sponsor:
Sirtsei Pharmaceuticals, Inc.
Location:
Code:
NCT06254612
Conditions
Major Depressive Disorder
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
SP-624
Placebo
ALTO-100ALTO-100 in Bipolar Disorder with Depression (BD-D)
Sponsor:
Alto Neuroscience
Location:
Code:
NCT06656416
Conditions
Bipolar Disorder I or II with a Major Depressive Episode
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
ALTO-100
Placebo
Telisotuzumab Vedotin vs. DocetaxelA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Sponsor:
AbbVie
Location:
Code:
NCT04928846
Conditions
Non Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Telisotuzumab Vedotin
Docetaxel
Fianlimab & CemiplimabA Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor:
Regeneron Pharmaceuticals
Location:
Code:
NCT05785767
Conditions
Advanced Non-Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
fianlimab
cemiplimab
Placebo
NMRA-335140-501Study to Assess the Safety and Effectiveness of NMRA-335140-501
Sponsor:
Neumora Therapeutics, Inc.
Location:
Code:
NCT06029439
Conditions
Major Depressive Disorder
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
NMRA-335140
DazodalibepA Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
Sponsor:
Amgen
Location:
Code:
NCT06104124
Conditions
Sjogren's Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Dazodalibep
Placebo
CentanafadineTrial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Location:
Code:
NCT05536414
Conditions
Major Depressive Disorder
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
Centanafadine
Escitalopram
Placebo
DazodalibepA Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Sponsor:
Amgen
Location:
Code:
NCT06245408
Conditions
Sjögren's Syndrome (SS)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Dazodalibep
Placebo